PI3Kγ stimulates a high molecular weight form of myosin light chain kinase to promote myeloid cell adhesion and tumor inflammation

• Published in: Nature communications Vol. 13; no. 1; p. 1768
• Main Authors: Schmid, Michael C., Kang, Sang Won, Chen, Hui, Paradise, Marc, Ghebremedhin, Anghesom, Kaneda, Megan M., Chin, Shao-Ming, Do, Anh, Watterson, D. Martin, Varner, Judith A.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.04.2022; Nature Publishing Group; Nature Portfolio
• Subjects: 13; 13/1; 13/21; 13/51; 14; 14/19; 38; 42; 42/109; 59; 631/250/580; 631/67/580; 631/80/79/1236; 82/80; 96; 96/31; Adhesion; Angiogenesis; Cancer; Cell activation; Cell adhesion; Cell Adhesion - physiology; Chains; Chemokines; Class Ib Phosphatidylinositol 3-Kinase - metabolism; Cytokines; Extravasation; Humanities and Social Sciences; Humans; Inflammation; Interleukins; Kinases; Leukocytes (granulocytic); Molecular Weight; Monocytes; multidisciplinary; Myeloid cells; Myeloid Cells - metabolism; Myosin; Myosin-light-chain kinase; Myosin-Light-Chain Kinase - metabolism; Neoplasms - genetics; Parenchyma; Rap1 protein; Science; Science (multidisciplinary); Tumors; Vascular cell adhesion molecule 1
• ISSN: 2041-1723; 2041-1723
• DOI: 10.1038/s41467-022-29471-6

Myeloid cells play key roles in cancer immune suppression and tumor progression. In response to tumor derived factors, circulating monocytes and granulocytes extravasate into the tumor parenchyma where they stimulate angiogenesis, immune suppression and tumor progression. Chemokines, cytokines and interleukins stimulate PI3Kγ-mediated Rap1 activation, leading to conformational changes in integrin α4β1 that promote myeloid cell extravasation and tumor inflammation Here we show that PI3Kγ activates a high molecular weight form of myosin light chain kinase, MLCK210, that promotes myosin-dependent Rap1 GTP loading, leading to integrin α4β1 activation. Genetic or pharmacological inhibition of MLCK210 suppresses integrin α4β1 activation, as well as tumor inflammation and progression. These results demonstrate a critical role for myeloid cell MLCK210 in tumor inflammation and serve as basis for the development of alternative approaches to develop immune oncology therapeutics. Myeloid cell recruitment during tumor inflammation depends on the VCAM-1 receptor integrin α4β1. Here the authors show that a high molecular weight form of myosin light chain kinase, MLCK210, is required for myeloid cell integrin α4β1 activation and adhesion and that MLCK210 inhibition reduces tumor growth and inflammation in preclinical cancer models.